MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epithelioid

Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in […]

Comments Off on National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples

Advances in Anatomic Pathology 2018 January [Link] Monaco S, Mehrad M, Dacic S Abstract Mesothelial proliferations can be diagnostically challenging in small specimens, such as body fluid cytology and small tissue biopsies. A great morphologic challenge for pathologists is the separation of benign reactive mesothelial proliferations from malignant mesotheliomas. Reactive mesothelial proliferations may have histologic […]

Comments Off on Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples

A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis

Anticancer Research 2017 December [Link] Matsubara T Abstract BACKGROUND: Malignant mesothelioma (MM) is a well-known malignant tumor that occurs in the pleura and is histopathologically classified into three subtypes. Lymphohistiocytoid mesothelioma (LHM) is considered a variant of epithelioid MM, and few cases have been reported. First case of LHM was reported by Henderson et al. […]

Comments Off on A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Comments Off on Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Oncoimmunology 2017 July [Link] Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC Abstract Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its […]

Comments Off on Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

Oncotarget 2017 September [Link] Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS Abstract BACKGROUND: To develop cancer antigen-targeted immunotherapeutic strategies for malignant pleural mesothelioma (MPM), we investigated the individual and coexpressions of the cancer-associated antigens mesothelin (MSLN), cancer antigen 125 (CA125), and Wilms tumor 1 […]

Comments Off on Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Asia-Pacific Journal of Clinical Oncology 2017 November [Epub ahead of print] [Link] Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S Abstract AIM: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has […]

Comments Off on PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation

The American Journal of Dermatopathology 2017 October [Epub ahead of print] [Link] Klebanov N, Reddy BY, Husain S, Silvers DN, Grossman ME, Tsao H Abstract Malignant pleural mesothelioma is a rare neoplasm of mesodermal origin. Cutaneous involvement of malignant pleural mesothelioma is a very rare entity, with only 11 cases reported in the literature. Here, […]

Comments Off on Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation

Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Oncotarget 2017 August [Link] Wang LM, Shi ZW, Wang JL, Lv Z, Du FB, Yang QB, Wang Y Abstract BACKGROUND: Conventional measurements are not always helpful in the diagnosis of malignant mesothelioma (MM). Increasing studies indicate that loss of BRCA1-associated protein 1 (BAP1) detected by immunohistochemistry (IHC) is a useful diagnostic marker for MM. In […]

Comments Off on Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

miR-30d is related to asbestos exposure and inhibits migration and invasion in NCI-H2452 cells

FEBS Open Bio 2017 August 30 [Link] Ju L, Wu W, Yin X, Xiao Y, Jia Z, Lou J, Yu M, Ying S, Chen T, Jiang Z, Li W, Chen J, Zhang X, Zhu L. Abstract Pleural malignant mesothelioma (MM) is a highly aggressive tumor that is typically related to asbestos exposure and has a […]

Comments Off on miR-30d is related to asbestos exposure and inhibits migration and invasion in NCI-H2452 cells